Ancora Releases Letter Regarding its Strong Opposition to H.B. Fuller’s High-Risk Attempt to Acquire U.K.-Based Advanced Medical Solutions

Key Terms

net debt financial

Net debt is the total amount a company owes after subtracting the cash and assets it has that can be used to pay off that debt. It shows how much debt is truly a burden, helping investors understand if a company is financially healthy or heavily borrowed. Think of it like calculating how much money you owe after using your savings to pay part of it.

adjusted ebitda financial

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

deleveraging financial

Deleveraging is the process of a company reducing the amount of debt it carries relative to its assets or equity, either by paying down loans, selling assets, or raising fresh equity. For investors it matters because lower debt typically means less financial risk and steadier cash flow—like removing weight from a backpack to make a hike safer and easier—while it can also slow growth if borrowing had been funding expansion.

m&a financial

M&A, short for mergers and acquisitions, involves one company combining with or purchasing another company to grow, streamline operations, or gain competitive advantages. For investors, M&A activity can signal potential for increased value, new opportunities, or changes in market dynamics, making it an important factor to watch in the business landscape.

poison pill financial

A poison pill is a defensive tactic a company’s board adopts to make an unwanted takeover much more costly or difficult, typically by allowing existing shareholders (but not the bidder) to buy additional shares or triggering dilution once a single buyer crosses a ownership threshold. For investors, it matters because it can protect a company’s long‑term plans and raise the price a bidder must pay, but it can also block or delay takeovers that might deliver a premium to shareholders.

strategic alternatives financial

Strategic alternatives are different options a company considers to improve its value or achieve its goals, such as selling the business, merging with another company, or restructuring operations. For investors, understanding these options is important because they can significantly impact the company's future direction and its stock value, often signaling potential changes or opportunities.

proxy fight regulatory

A proxy fight is a battle between groups of shareholders who try to persuade other investors to let them vote on company matters on their behalf so they can replace board members or change company direction. Think of it like rival teams campaigning for the right to pick the coach; the outcome can reshape management, strategy and risk levels, create short-term uncertainty, and therefore affect a company’s stock price and investor returns.

total shareholder returns financial

Total shareholder returns measures the full financial gain an investor receives from owning a company's stock over a period, combining the change in the share price and any cash payments to shareholders (like dividends), typically assuming those payments are reinvested. It matters because it shows the real, overall payoff from an investment — like tracking both how much a house rises in value and the rental income it generates — and lets investors compare performance across companies or time.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Contends the Reckless Pursuit of AMS Contradicts Management’s March 26^th Public Commitment to Avoid Near-Term Deals in Favor of Necessary Deleveraging

Highlights the Potential Acquisition Would Increase Leverage to Above 4.0x Net Debt / Proforma Adjusted EBITDA and Exacerbate the Company’s Depressed Valuation Multiple

Notes Management Lacks Experience Successfully Integrating Transformative Acquisitions Involving New Product Categories with Regulatory Complexities in Foreign Geographies

Urges H.B. Fuller’s Board to Abandon its Irresponsible Pursuit of AMS and Conduct a Full Review of Strategic Alternatives, Including Evaluating Sale Options Following Apparent Buyer Interest

Visit www.SaveHBFuller.com to Share Your Feedback

CLEVELAND--(BUSINESS WIRE)-- Ancora Holdings Group, LLC today released the below letter to H.B. Fuller Company (NYSE: FUL), which outlines the firm’s strong opposition to an acquisition of Advanced Medical Solutions Group plc (“AMS”) or any other business. Visit www.SaveHBFuller.com for important information and updates.

***

May 23, 2026

H.B. Fuller Company
Attention: The Board of Directors (the “Board”)
1200 Willow Lake Boulevard, P.O. Box 64683
St. Paul, Minnesota 55164-0683

Subject: The Reasons for Abandoning the Reckless Pursuit of AMS / Initiating a Strategic Review

Members of the Board,

Ancora Holdings Group, LLC (collectively with its affiliates, “Ancora” or “we”) is the beneficial owner of more than 2% of the outstanding common stock of H.B. Fuller Company (“H.B. Fuller” or the “Company”). Given our belief that H.B. Fuller has attractive businesses and a depressed public market valuation, we intend to continue increasing our stake in the Company. We plan to proceed in this manner despite our reservations about the competence, candor and strategic judgment that have been exhibited by management and the Board. As Ancora has repeatedly demonstrated in its engagements over the years, we will fix poor leadership from the inside – or from the outside – once committed to an investment.

We appreciate being given the opportunity to constructively engage with management over the course of the spring. Comments made by H.B. Fuller on the Q1 2026 earnings call, as well as during private one-on-one conversations with us, gave us comfort that we were aligned when it came to focusing on deleveraging and not pursuing any near-term M&A. You can only imagine our shock when we saw the disclosure on May 21^st regarding the Company's offer, made in April, to acquire Advanced Medical Solutions Group plc (“AMS”). Throughout our good faith engagement, H.B. Fuller never indicated any interest in abandoning its deleveraging-first focus and the Company never offered to put us under a non-disclosure agreement to discuss its renewed focus on deals. We – and presumably many other shareholders – feel completely misled.

The purpose of today’s letter is to convey our strong opposition to the pursuit of AMS or any other material purchase, and we call on the Board to first conduct a full review of strategic alternatives (including evaluating a sale of all or parts of the business) as an essential initial step. In hindsight, we are not surprised that management and their advisors are apparently advocating for a large cross-border acquisition that will increase leverage and introduce numerous operating risks, including with respect to entering new categories with fragmented regulatory regimes across Europe. After all, these individuals have little to no personal capital at risk. You, however, owe fiduciary obligations to the owners of the Company, who do have significant capital at risk.

The silver lining is the Board still has time to slam the brakes on an acquisition of AMS before further damaging H.B. Fuller’s credibility with shareholders and impairing the Company’s value in the market. When contemplating how this acquisition looks from the perspective of shareholders, please consider the following:

1. Acquiring AMS would completely impugn the credibility of management and the Board in the eyes of the investment community. As a reminder, leadership stated on H.B. Fuller’s most recent earnings call that “we will pause on closing deals in the near term, focusing more cash deployment on share repurchases, while we deliver on our commitment to achieve our target of 2.5x to 3x net debt to EBITDA.” It seems the Board either ignored or was unaware of the Company’s own commitment when authorizing the pursuit of AMS. We believe Ancora is part of a growing crowd of shareholders who are already outraged by the Company’s attempt to break its two-month-old deleveraging pledge in favor of a bizarre deal.
   
   
2. Acquiring AMS or any material acquisition appears like a de facto “poison pill” intended to chill what we believe is meaningful acquirer interest. We are concerned the full Board may not be aware of the strong interest that financial sponsors have in acquiring H.B. Fuller and other industrial chemical companies. Based on our diligence and discussions with long-standing industry contacts, we are highly confident that leadership has been approached by credible buyers. After all, H.B. Fuller is the world’s only pure-play, publicly listed adhesives business. This is why shareholders will very likely agree with us that any acquisition represents a thinly veiled entrenchment maneuver. Given the meaningful discount H.B. Fuller currently trades at relative to the Company’s intrinsic value, we question how the Board could allow management to pursue this type of capital allocation decision without first running a comprehensive strategic review.
   
   
3. The prospective acquisition of AMS represents an extremely risky, quasi-transformational international acquisition that is completely out of management’s depth. This type of deal would propel the Company into a category where it has no significant product experience, no in-market experience and no relevant regulatory expertise. The risk is amplified by the Company relying upon a historically ineffective U.S.-based leadership team to integrate an international business across a fragmented European footprint. It is unfathomable to us that the Board would allow a CEO who has failed to generate shareholder value since beginning in the role to pursue such a high-risk acquisition. Lastly, geopolitical issues have increased the likelihood of supply chain disruptions and, in turn, industry volatility that makes it the worst possible time for H.B. Fuller to “bet the house” on AMS.
   
   
4. The deal would increase the Company’s leverage to above 4.0x Net Debt / Proforma Adjusted EBITDA. This level of leverage would put further pressure on the Company's capital structure and already depressed valuation. The move also directly undermines the commitment to achieve balance sheet leverage of 2.5x-3.0x made on the Q1 2026 earnings call. There is a long list of examples of leverage constraining a company’s trading multiple. H.B. Fuller already trades at a significant discount to its intrinsic value, public peers and adhesive transaction comparables. Levering up to more than 4.0x only increases risk for shareholders while management and the Board entrench themselves by betting the house on transformational M&A.
   
   
5. The deal would exacerbate the negative overhang on the Company's poor valuation multiple – further punishing shareholders who have endured share price declines and valuation multiple compression. It is important to keep in mind that investors have endured total shareholder returns, inclusive of dividends, of approximately -25% during the tenure of Chief Executive Officer Celeste Mastin. Moreover, it would be further dilutive to H.B. Fuller’s beleaguered valuation multiple to buy something at 11x-12x EBITDA while the Company trades at roughly 7.5x EBITDA. The Company is arguably already a conglomerate in the adhesives space, meaning acquiring a company with two-thirds of its portfolio in unrelated businesses will only exacerbate the conglomerate discount that H.B. Fuller currently trades at.

To be clear, the pursuit of AMS must be abandoned in favor of a comprehensive review of all strategic alternatives – the foundation of any well-governed transaction evaluation process seeking to maximize shareholder value. Although our engagement with Ms. Mastin appears to have been disingenuous, we welcome the opportunity to adjust the scope of our June 10^th meeting to include any directors interested in hearing what will be best for H.B. Fuller’s owners. As a result of hearing from Ancora and presumably other shareholders, we are confident the Board will quickly begin to see the need to abandon the pursuit of any acquisition. In the same spirit, the Board should not even consider entering into a bidding war for AMS or seeking to sweeten its existing proposal to entice AMS to turn away other suitors.

In closing, although we are prepared to hold leadership accountable for any value-destructive and ill-timed capital allocation blunders via a proxy fight next year, the goal from the start of our monthslong engagement with H.B. Fuller has been to work together in a constructive manner to enhance value for shareholders. Our engagements at companies like Berry Global Group, Inc., C.H. Robinson Worldwide, Inc. and Mueller Water Products, Inc. reflect our preference for working behind the scenes to catalyze value creation. You are welcome to draw us into a fight, but it is hard to remember the last time that worked out well for a corporate leadership team. Despite our poor start with Ms. Mastin and the shocking news of the attempted purchase of AMS, we remain hopeful that we can reset during our intended June 10^th meeting and help ensure a proper review of all strategic alternatives is the tip of the spear for any transaction-related decisions.

Regards,

Fredrick D. DiSanto Chairman and Chief Executive Officer Ancora Holdings Group LLC

James Chadwick President Ancora Alternatives LLC

***

Visit www.SaveHBFuller.com to share your views on the potential acquisition. There is a limited window of time to act.

About Ancora

Founded in 2003, Ancora Holdings Group, LLC offers integrated investment advisory, wealth management, retirement plan services and insurance solutions to individuals and institutions across the United States. The firm is a long-term supporter of union labor and has a history of working with union groups and public pension plans to deliver long-term value. Ancora’s comprehensive service offering is complemented by a dedicated team that has the breadth of expertise and operational structure of a global institution, with the responsiveness and flexibility of a boutique firm. Ancora Alternatives is the alternative asset management division of Ancora Holdings Group, investing across three primary strategies: activism, multi-strategy and commodities. For more information about Ancora Alternatives, please visit www.ancoraalts.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260526137974/en/

Longacre Square Partners LLC
Casie Connolly (U.S.) / Humza Vanderman (U.K.)
cconnolly@longacresquare.com / hvanderman@longacresquare.com

Source: Ancora Holdings Group, LLC